Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

Clinical trial NCT07691515 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07691515
Sponsor: Zhejiang Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Intrahepatic Cholangiocarcinoma (Icc)

Start date: 2026-07-01
Primary completion: 2030-01-01
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.